---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-168878"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2022-06-07T23:59:59+00:00"
generated_at: "2026-06-25T03:52:40.515253+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CEO Manuel Aivado appointed principal financial officer after CFO Richard Wanstall resigns

## Summary
- CFO Richard J. Wanstall resigned effective May 6, 2022.
- On June 5, 2022, CEO Manuel Aivado appointed as principal financial and accounting officer.
- Dr. Aivado has served as President and CEO since September 2018; no arrangement or family relationships.
- No transactions disclosed between Aivado and company per Item 404(a).

## SEC filing metadata
- accession: 0001193125-22-168878
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2022-06-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312522168878/0001193125-22-168878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312522168878/d323390d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-168878
- JSON: https://secwatch.observer/filing/0001193125-22-168878.json
- Plain text: https://secwatch.observer/filing/0001193125-22-168878.txt

## Key facts
- Executive change
  Richard J. Wanstall resigned as Chief Financial Officer at Rein Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Richard J. Wanstall, the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, notified the Company of his resignation, effective May 6, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312522168878/0001193125-22-168878-index.htm
- Executive change
  Manuel Aivado was appointed as principal financial officer and principal accounting officer at Rein Therapeutics, Inc..
  - Action: appointed
  - Role: principal financial officer and principal accounting officer
  source text: On June 5, 2022, the Board of Directors of the Company appointed Manuel Aivado, M.D., Ph.D., the Company’s President and Chief Executive Officer to serve as the Company’s principal financial officer and principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312522168878/0001193125-22-168878-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.